Two of the big companion diagnostic players, Qiagen NV and Myriad Genetics Inc., have signed new deals.
Qiagen’s agreement targets circulating tumor cells
More Companion Diagnostic Deals For Qiagen And Myriad
Qiagen’s agreement Tokai Pharmaceuticals targets circulating tumor cells, and Myriad Genetics has extended its partnership with BioMarin Pharmaceutical focused on Myriad's myChoice HRD companion diagnostic.